Giles Lisa M. 4

What Happened

• Lisa M. Giles, a director of Milestone Pharmaceuticals, was granted a derivative award on June 10, 2026 covering 77,000 shares. The Form 4 reports an acquisition at $0.00 per share (transaction code A), indicating a stock option/award granted as compensation — no cash was paid by Giles. This was not an exercise or sale; no shares were sold immediately.

Key Details

• Transaction date: 2026-06-10; reported on Form 4 filed 2026-06-12 (timely filing).
• Transaction type/code: A (award/grant) — derivative security (option).
• Quantity and price: 77,000 shares reported at $0.00 per share.
• Shares owned after transaction: Not disclosed in this filing.
• Footnote: The option vests in twelve equal monthly installments beginning July 10, 2026, but will be fully vested on the date of the issuer’s next annual meeting, provided Giles continues service through each vesting date.

Context

• This is a compensation grant (option award) to a director, common for aligning long-term interests with shareholders; it is not an open-market purchase or sale and does not by itself indicate Giles bought or sold shares. The award vests over time (with accelerated full vesting at the next annual meeting), so Giles will only realize the economic interest if and when the options vest and are later exercised or converted.